Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors

Authors: Piiper, A.; Zeuzem, S.

Source: Current Pharmaceutical Design, Volume 10, Number 28, November 2004 , pp. 3539-3545(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

G protein-coupled receptors (GPCRs) can utilize receptor tyrosine kinases (RTKs) to mediate important cellular responses such as proliferation, differentiation and survival. Recent advances in the field suggest that GPCRinduced transactivation of RTKs might be important for diseases such as cancer and cardiac hypertrophy. Depending on the receptor and cell type, GPCR signaling involves activation of several different RTKs. By activating different subsets of RTKs, GPCRs can fine-tune their effects on target cells. Furthermore, RTK-independent signaling pathways also initiated by GPCRs may modify the biological read out of the transactivated RTKs. This review focuses on the mechanisms how GPCRs and intracellular messengers elicit transactivation of different RTKs and the resulting different biological responses.

Keywords: transactivation; map kinases; cell survival; egf receptor; pdgf receptor; trk; akt

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612043382936

Affiliations: 1: Department of Internal Medicine II, University of Saarland, D-66421 Homburg / Saar, Germany.

Publication date: 2004-11-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.